⚠ Leadership Update: Paul Hudson served as CEO of Sanofi from September 2019 until February 2026. He was removed by the Board on February 12, 2026. Olivier Charmeil is serving as interim CEO, and Belén Garijo (former CEO of Merck KGaA) will formally assume the CEO role at Sanofi’s Annual General Meeting on April 29, 2026.
Sanofi S.A., the French multinational pharmaceutical giant and the world’s fifth-largest drugmaker by prescription sales, appointed Paul Hudson as CEO in September 2019. During his tenure, Hudson transformed Sanofi’s portfolio by pivoting from cardiovascular and diabetes drugs toward immunology, oncology, and vaccines. His signature achievement was growing Dupixent into a €13+ billion blockbuster, making it one of the best-selling medicines in the world. However, a string of R&D setbacks in 2025 and the lack of a clear successor to Dupixent ultimately led the board to remove him in February 2026. Under Hudson, Sanofi’s annual net sales grew from roughly €36 billion (2019) to over €43 billion (2025).
(Suggested: Novartis CEO Email & Net Worth – Vas Narasimhan)
Paul Hudson – Quick Facts
| Paul Hudson — At a Glance | |
| Full Name | Paul Ashley Hudson |
| Position | Former Chief Executive Officer (removed Feb 2026) |
| Company | Sanofi S.A. (Euronext: SAN / NASDAQ: SNY) |
| Age | 58 years (born October 14, 1967) |
| Nationality | British |
| Education | B.A. Economics, Manchester Metropolitan University; Marketing Diploma, Chartered Institute of Marketing |
| Net Worth (2026) | €10–15 Million (est.) |
| Total Compensation | ~€10.45 Million (FY2024) |
| CEO Tenure | September 2019 – February 17, 2026 |
| Previous Role | CEO, Novartis Pharmaceuticals (2016–2019) |
| [email protected] | |
| linkedin.com/in/paulhudsonprofile | |
Sanofi Competitors
Sanofi competes with the largest multinational pharmaceutical companies across immunology, oncology, vaccines, and rare diseases. The key competitors of Sanofi include:
- Pfizer Inc. – vaccines, oncology, and a broad therapeutic portfolio
- Novartis AG – innovative therapies, immunology, and cardiovascular treatments
- AstraZeneca PLC – oncology, respiratory, and cardiovascular drugs
- Merck & Co. – oncology (Keytruda), vaccines, and infectious disease
- AbbVie Inc. – immunology (Humira/Skyrizi), oncology, and neuroscience
- Eli Lilly and Company – diabetes, obesity, oncology, and immunology
- GSK plc – vaccines, respiratory, and HIV treatments
- Roche Holding AG – oncology, diagnostics, and personalized medicine
Paul Hudson Net Worth 2026 – Sanofi CEO Salary
As of 2026, Paul Hudson’s net worth is estimated at approximately €10–15 million, based on his disclosed Sanofi stock holdings, vested performance shares, and accumulated compensation over six years as CEO. According to SEC and AMF filings, his direct shareholding in Sanofi was valued at approximately €11.3 million. His estimated net worth was at least $6.4 million from stock holdings alone as of late 2025, with additional wealth from vested equity and cash compensation.
Sanofi CEO Compensation Breakdown (FY2024)
| Component | Amount (EUR) | Share |
|---|---|---|
| Base Salary (Fixed) | €1,400,000 | 13.4% |
| Annual Variable (Bonus) | €2,566,200 | 24.5% |
| Performance Share Awards | €5,971,350 | 57.1% |
| Pension Contribution | €495,775 | 4.7% |
| Benefits in Kind | €13,497 | 0.1% |
| TOTAL | €10,446,822 | 100% |
Sanofi Net Worth 2026 – Is Sanofi Profitable?
Yes, Sanofi is a highly profitable company. Under Paul Hudson’s leadership, Sanofi grew into one of the world’s most valuable pharmaceutical companies, with a market capitalization of approximately $117 billion (as of February 2026). The company’s full-year 2024 net sales reached €41.1 billion, with IFRS net income of €5,744 million. Dupixent alone generated over €13 billion in 2024 sales, and Beyfortus became a blockbuster in its first full year with €1.7 billion.
Sanofi Financial Summary (FY2024)
| Metric | Value | YoY Change |
|---|---|---|
| Market Capitalization | ~$117B | — |
| Net Sales (Revenue) | €41.1B | ▲ 11.3% (CER) |
| Net Income (IFRS) | €5,744M | ▲ Positive |
| Business Operating Income | €11,343M | ▲ 7.6% (CER) |
| BOI Margin | 28.6% | ▼ 1.0pp |
| Gross Margin | 75.7% | — |
| Business EPS | €7.12 | ▲ 4.1% (CER) |
| Dupixent Sales | €13.1B | ▲ 23.1% |
| Dividend per Share | €3.92 | ▲ 30th consecutive increase |
| Employees | ~82,900 | — |
(Recommended: AstraZeneca CEO Email & Net Worth – Pascal Soriot Salary)
Sanofi CEO Email Address | Paul Hudson Contact
Below are the contact details and social media profiles for former Sanofi CEO Paul Hudson:
| Contact Information | |
| Email Address | [email protected] |
| linkedin.com/in/paulhudsonprofile | |
| Corporate HQ | 46–48 Avenue de la Grande Armée, 75017 Paris, France |
| Corporate Website | sanofi.com |
| Investor Relations | sanofi.com/en/investors |
Career & Education – Company, University, & College
Paul Hudson built a distinguished career spanning three decades across some of the world’s largest pharmaceutical companies. He began in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK in the 1990s, gaining foundational experience in the healthcare industry.
In 2006, Hudson joined AstraZeneca as Vice President and Primary Care Director in the UK. Over the next decade, he rose through increasingly senior international roles: Marketing Company President in Spain (2008), President of AstraZeneca Japan (2011), and finally Executive Vice President of North America and President of AstraZeneca US (2013–2016). His ability to drive growth across diverse markets earned him a reputation as one of pharma’s most effective commercial leaders.
(Related: Pfizer CEO Email & Net Worth – Albert Bourla Salary)
In 2016, Hudson was appointed CEO of Novartis Pharmaceuticals, the largest division of Swiss pharma giant Novartis, where he oversaw a portfolio of blockbuster drugs and led commercial strategy. After three years at Novartis, Sanofi recruited him as Chief Executive Officer in September 2019, replacing Olivier Brandicourt.
At Sanofi, Hudson executed a major transformation: divesting non-core assets, pivoting R&D toward immunology and vaccines, and growing Dupixent from a promising launch into the company’s crown jewel. However, R&D setbacks in late 2025 and concerns about the pipeline beyond Dupixent led the board to remove him on February 12, 2026.
Paul Hudson Career Timeline
| Period | Role | Company |
|---|---|---|
| 1990s | Sales & Marketing (various roles) | GlaxoSmithKline UK |
| 1990s–2006 | Sales & Marketing (various roles) | Sanofi-Synthélabo UK |
| 2006–2008 | VP & Primary Care Director, UK | AstraZeneca |
| 2008–2011 | Marketing Company President, Spain | AstraZeneca |
| 2011–2013 | President, AstraZeneca Japan | AstraZeneca |
| 2013–2016 | EVP North America & President, AstraZeneca US | AstraZeneca |
| 2016–2019 | Chief Executive Officer, Novartis Pharmaceuticals | Novartis AG |
| 2019–2026 | Chief Executive Officer | Sanofi S.A. |
Education
| Institution | Degree / Program | Website |
|---|---|---|
| Manchester Metropolitan University | B.A. in Economics | mmu.ac.uk |
| Chartered Institute of Marketing | Diploma in Marketing | cim.co.uk |
| Manchester Metropolitan University | Honorary Doctorate (2018) | mmu.ac.uk |
Paul Hudson Wiki – Age, Wife, Family, & More
Paul Ashley Hudson (age 58, born October 14, 1967) is a British businessman who spent over three decades in the global pharmaceutical industry. He and his wife Sandra have three children. When Hudson took the Sanofi CEO role in 2019, the family relocated from Switzerland to Paris and took French lessons to integrate into their new home. Sandra Hudson maintains a low public profile.
Hudson is an ardent Manchester United football fan and has spoken publicly about how his working-class upbringing in the UK shaped his leadership philosophy. He has said that integrity, empowerment, inspiration, and action are the values that help transform oneself from within. He chose the healthcare field because he wanted to change people’s lives positively, and he believes that medicines must be the best at saving, changing, and transforming a patient’s life.
Notable Achievements & Recognitions
- Dupixent Growth: Grew Dupixent from a new launch into a €13+ billion blockbuster — one of the world’s best-selling drugs
- Portfolio Transformation: Shifted Sanofi’s R&D focus from cardiovascular/diabetes to immunology, oncology, and vaccines
- Beyfortus Launch: Oversaw the launch of Beyfortus (RSV prevention), which became a blockbuster (€1.7B) in its first full year
- World Economic Forum: Regular participant and speaker at WEF Davos on topics including healthcare innovation and AI in pharma
- TED Speaker: Featured speaker at TED on healthcare leadership and pharmaceutical innovation
- Honorary Doctorate: Awarded honorary doctorate by Manchester Metropolitan University in 2018
(Suggested: Roche CEO Email & Net Worth – Thomas Schinecker Salary)
About Sanofi
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. Founded in 1973 as a subsidiary of Elf Aquitaine, the company grew through a series of major mergers: with Synthélabo in 1999 (becoming Sanofi-Synthélabo), and with Aventis in 2004 (becoming Sanofi-Aventis). The company simplified its name to Sanofi in 2011.
| Business Segment | Key Products | Description |
|---|---|---|
| Specialty Care | Dupixent, Kevzara, Altuviiio | Immunology, hematology, and rare diseases |
| Vaccines | Beyfortus, Fluzone, Vaxigrip | World’s largest vaccine producer via Sanofi Pasteur |
| General Medicines | Lantus, Toujeo, Plavix | Diabetes, cardiovascular, and established therapies |
| Consumer Healthcare | Doliprane, Allegra, Mucosolvan | OTC medicines (Opella unit — partial sale announced) |
Sanofi trades on Euronext Paris (ticker: SAN) and on NASDAQ (ticker: SNY). As of 2024, the company employed approximately 82,900 people worldwide and operated in over 100 countries. The company’s annual dividend has increased for 30 consecutive years.
Frequently Asked Questions (FAQ)
Who is the current CEO of Sanofi?
As of February 2026, Olivier Charmeil is serving as interim CEO of Sanofi following the removal of Paul Hudson on February 12, 2026. Belén Garijo, the former CEO of Merck KGaA, has been named the new CEO and will formally take the role at Sanofi’s Annual General Meeting on April 29, 2026.
What is Paul Hudson’s net worth in 2026?
As of 2026, Paul Hudson’s net worth is estimated at approximately €10–15 million, based on his disclosed Sanofi shareholdings (valued at approximately €11.3 million), vested performance shares, and accumulated compensation from six years as CEO.
What was the Sanofi CEO’s salary?
Paul Hudson’s total compensation for fiscal year 2024 was approximately €10.45 million, comprising a €1.4 million base salary, €2.57 million annual bonus (183.25% of base), €5.97 million in performance share awards, and €0.5 million in pension contributions. For 2025, his base salary was increased to €1.6 million.
What is the Sanofi CEO’s email address?
Paul Hudson’s email address at Sanofi was [email protected]. He can also be reached via LinkedIn. For general corporate inquiries, visit sanofi.com.
Why was Paul Hudson removed as Sanofi CEO?
Sanofi’s board removed Paul Hudson on February 12, 2026 after a series of underwhelming R&D trial results in 2025 that contributed to a roughly 25% decline in the company’s share price. The board cited a need for more “rigor” and concerns about the lack of a clear pipeline successor to blockbuster drug Dupixent, whose key patents expire in the early 2030s. Additionally, vaccine sales guidance for 2026 was “slightly negative” due in part to U.S. policy changes.
Is Sanofi a profitable company?
Yes, Sanofi is highly profitable. In fiscal year 2024, the company reported net sales of €41.1 billion, IFRS net income of €5,744 million, and business operating income of €11,343 million. The gross margin was 75.7%, and the company declared a dividend of €3.92 per share — its 30th consecutive annual increase.
Article last updated:March 2026March 2, 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including Sanofi’s official filings (AMF/SEC), corporate press releases, annual reports, and reputable news outlets. Net worth figures are estimates and may vary by source. This content is provided for informational purposes only and does not constitute financial or investment advice.